iTeos Therapeutics (NASDAQ:ITOS) Given “Outperform” Rating at Wedbush

Wedbush reiterated their outperform rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a report released on Tuesday,RTT News reports. The brokerage currently has a $25.00 target price on the stock.

A number of other analysts also recently commented on the stock. Wells Fargo & Company assumed coverage on shares of iTeos Therapeutics in a report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Monday, September 16th. Finally, JPMorgan Chase & Co. cut their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Monday, August 12th.

iTeos Therapeutics Stock Down 2.0 %

iTeos Therapeutics stock opened at $9.19 on Tuesday. The company has a fifty day simple moving average of $10.84 and a 200-day simple moving average of $14.07. The firm has a market capitalization of $335.62 million, a price-to-earnings ratio of -3.06 and a beta of 1.39. iTeos Therapeutics has a 52-week low of $8.41 and a 52-week high of $18.75.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ITOS. nVerses Capital LLC lifted its stake in iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after acquiring an additional 1,700 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in iTeos Therapeutics by 60.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after purchasing an additional 2,646 shares during the period. Quest Partners LLC lifted its position in shares of iTeos Therapeutics by 914.7% during the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after purchasing an additional 9,934 shares in the last quarter. US Bancorp DE boosted its stake in shares of iTeos Therapeutics by 206.0% in the third quarter. US Bancorp DE now owns 12,076 shares of the company’s stock valued at $123,000 after purchasing an additional 8,129 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of iTeos Therapeutics in the third quarter valued at approximately $126,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.